Pyxis-Biosion deal readies anti-SIGLEC15 mAb for clinic behind NextCure program

Pyxis’ deal to obtain most worldwide rights to an anti-SIGLEC15 antibody from China-based Biosion sets up the Massachusetts-based biotech with a second product poised for IND submission this year, which it believes could be best-in-class.

Pyxis Oncology Inc. (NASDAQ:PYXS) is paying Biosion Inc. $10 million up front for ex-Greater China rights to BSI-060T, which Pyxis is renaming PYX-106. The deal includes up to $222.5 million in milestones, plus royalties; Biosion retains rights in mainland China, Hong Kong, Macau and Taiwan...